Weight-Loss Jabs, Gallstones and the Pancreas — the Evidence

Do weight-loss jabs cause gallstones?

Yes — there is a genuine, measurable link, and it is the clearest of the two risks on this page. In a large systematic review and meta-analysis of 76 randomised controlled trials covering 103,371 participants (JAMA Internal Medicine, 2022), people taking a GLP-1 receptor agonist had about a 37% higher risk of gallbladder or biliary disease overall (relative risk 1.37, 95% confidence interval 1.23–1.52). Broken down, that included a higher risk of gallstones (cholelithiasis, RR 1.27) and of gallbladder inflammation (cholecystitis, RR 1.36).

Importantly, the risk was not the same for everyone. It was:

• Higher when used for weight loss (RR 2.29) than for type 2 diabetes (RR 1.27) — likely because weight-loss use means larger, faster weight loss.
• Higher at higher doses (RR 1.56) than at lower doses.
• Higher with longer treatment.

To keep this in proportion: gallbladder problems are still an uncommon event for any one person, and for most people the benefits of these medicines outweigh this risk. But it is real, it is dose-related, and it is worth knowing about — especially in the first months when weight is coming off fastest.

Why does losing weight cause gallstones?

Much of the gallbladder risk is thought to come from the weight loss itself, not a direct toxic effect on the gallbladder. When you lose weight quickly, the balance of cholesterol and bile salts in the gallbladder shifts, and the gallbladder may empty less often — both of which make cholesterol gallstones more likely to form. This is a well-recognised effect of any rapid weight loss, which is why gallstones are also common after weight-loss (bariatric) surgery and very low-calorie diets. Because GLP-1 medicines are powerful at reducing appetite and driving weight loss, they carry this same downstream risk.

Do weight-loss jabs cause pancreatitis?

This is more nuanced. Acute pancreatitis is listed as an uncommon but serious side effect of GLP-1 medicines in their UK product information, and the MHRA and European Medicines Agency continue to monitor it closely. But when researchers pool the large randomised trials, a clear increase in risk does not reliably show up:

In plain terms: across tens of thousands of trial participants, people on a GLP-1 medicine were not clearly more likely to get pancreatitis than those on placebo or another treatment. The confidence intervals cross 1.0, meaning any true effect — if it exists — is small.

Two honest caveats keep this from being an all-clear. First, obesity and type 2 diabetes themselves raise the background risk of pancreatitis, so it is hard to fully separate the drug from the conditions it treats. Second, the people at highest risk — those with a history of pancreatitis — were generally excluded from these trials, so the evidence tells us less about them. That is exactly why the safety warning stays on the label.

What the UK label and MHRA say

UK prescribing information for semaglutide and tirzepatide reflects this careful position:

• Pancreatitis: if acute pancreatitis is suspected, the medicine should be stopped; if it is confirmed, treatment should not be restarted. These medicines have not been studied in people with a history of chronic pancreatitis, so caution is advised.
• Gallbladder: gallstones and gallbladder inflammation are recognised as possible side effects, and patients are told to seek advice for severe tummy pain.
• Monitoring: the MHRA and EMA list pancreatitis as an uncommon adverse effect and continue post-marketing surveillance rather than having established a firm causal link.

None of this is a reason to stop a medicine on your own. It is a reason to report new symptoms promptly so a clinician can decide.

Red-flag symptoms: what to look for

Both conditions cause tummy pain, and telling them apart is a job for a clinician — but knowing the warning signs helps you act quickly.

The clinician pathway: who to talk to and when

• Before you start: tell your prescriber if you have ever had pancreatitis, gallstones or gallbladder problems, or a family history of them. This helps them weigh up whether a GLP-1 medicine is right for you.
• While you’re on it: report any new, severe or persistent tummy or back pain to your GP or pharmacist promptly — don’t just push through it. Ask about a check if you develop gallbladder-type pain after fatty meals.
• If pancreatitis is suspected: a clinician will usually arrange a blood test (amylase or lipase) and sometimes a scan, and will advise you to stop the medicine while you are assessed.
• Never stop or change a diabetes medicine on your own because of these worries — that can be dangerous. Any change should be a shared decision with your GP, pharmacist or specialist.

Should this change your decision to take a weight-loss jab?

For most people without a history of pancreatitis or gallbladder disease, these risks are uncommon and manageable, and are weighed against real benefits for weight and metabolic health. The sensible approach is not to avoid treatment out of fear, but to go in informed: have an honest conversation with your prescriber about your personal history, know the red-flag symptoms, and act fast if they appear. If you have had pancreatitis before, that is an important conversation to have before starting.

Related reading